There is increasing evidence of fraud in clinical research, and one aspect concerns trading in pharmaceutical company shares by people who may have confidential information about the results of clinical trials.
Plainly this has implications for honest investigators, who may find themselves exposed to such allegations.
In this paper Dr D S Freestone and Mr H Mitchell, QC, identify three interlinked issues which they think underlie the potential for these allegations.
They are pressure for premature or inappropriate communication of research results; trading in pharmaceutical company shares by academic clinical investigators; and the possibility that clinical investigators might succumb to temptation.
Mots-clés Pascal : Homme, Recherche scientifique, Médecine, Document publié, Fraude
Mots-clés Pascal anglais : Human, Scientific research, Medicine, Published document
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0453193
Code Inist : 002B30A09. Création : 199406.